

Aeromics, Simcere team up for anti-edema therapy in Greater China

06 November 2019 | News

Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China

Simcere Pharmaceutical Group and Aeromics, Inc. have announced collaboration and exclusive license agreement for AER-271, a clinical-stage anti-edema therapy, being developed for the treatment of stroke and other indications, in Greater China (mainland China, Hong Kong, Macau and Taiwan). According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.

Thomas Zindrick, Aeromics' Executive Vice Chairman said, "We are delighted to be working with Simcere to develop AER-271 in China. Simcere's leading position in the Greater China stroke market, their strengths in manufacturing and the collaborative nature of their team made for an ideal partner for Aeromics."

Dr. Pin Wang, CSO of Simcere stated on the collaboration, "Edema is a serious complication among many common illnesses of the central nervous system (CNS) such as brain injury and cerebrovascular diseases, with a huge unmet medical need. Aeromics has an excellent research team and expertise in the stroke area, while Simcere has extensive experience in the drug development and commercialization of CNS diseases. We are pleased to have the opportunity to collaborate with Aeromics and hope we will bring AER-271 to patients soon with our joint efforts."

Dr. Peter Agre, Aeromics Board member, the 2003 Nobel Prize in Chemistry for discovery of the aquaporin water channels and commented, "By bringing together the complementary expertise of Aeromics and Simcere, I am very gratified we will together advance the development of a therapeutic for a significant unmet medical need, based on the initial insights into aquaporin biology."

Under terms of the collaboration, Aeromics will receive an up-front payment and additional payments contingent on certain development, regulatory, and commercial milestones, plus tiered royalties on net sales ranging from high single digit to double digit percentages.

Simcere will be responsible for leading development and commercialization of AER-271 in Greater China and will receive a single-digit percentage royalty from the net sales of AER-271 in the rest of the world. Detailed financial terms were not

disclosed.